Key Highlights

  • TransCode Therapeutics (NASDAQ:RNAZ) recorded a non-cash Impairment of USD 102.0 million on its Seviprotimut-L asset in the third quarter of 2026.
  • Third-quarter operating loss was USD 109.7 million, and the nine-month net loss was about USD 131.9 million.
  • Cash was approximately USD 4.6 million at September 30, 2026, which management expects to fund operations into approximately the first quarter of 2027.
  • The board began a formal strategic process on October 28, 2026 to evaluate Options for the company and its oncology portfolio.

Impairment Drives a Quarterly Operating Loss of USD 109.7 Million

TransCode Therapeutics (NASDAQ:RNAZ) filed its Quarterly Report on November 16, 2026. The clinical-stage company develops cancer drugs, led by TTX-MC138, an oligonucleotide candidate aimed at metastatic tumors that overexpress microRNA-10b. In the quarter it wrote down in-process Research and Development tied to Seviprotimut-L, which it obtained in the October 2025 Polynoma acquisition, by USD 102.0 million, cutting the carrying amount of USD 114.3 million to an estimated Fair Value of USD 12.3 million. Goodwill of USD 25.7 million had no accumulated impairment as of September 30, 2026. The filing links the charge to the sustained fall in the share price and market value, together with limited funding to advance the asset. Total operating expenses reached USD 109.7 million, compared with USD 4.6 million a year earlier.

Going Concern Doubt and the Yorkville Notes

Management concluded that substantial doubt exists about the company's ability to continue as a going concern. Nine-month cash used in operations was about USD 18.0 million and the accumulated Deficit was about USD 229.8 million. The company drew USD 1.0 million and USD 5.0 million convertible notes from Yorkville under a standby Equity purchase agreement that allows sales of up to USD 14 million of shares. In September 2026 it prepaid USD 840,975, and an amortization event occurred in November 2026 because the daily average price stayed below the floor price, so monthly cash payments are due unless waived. The company is in discussions with the lender, and there is no assurance of relief. Management plans include the strategic process, further equity or Debt Financing and cutting planned spending, though the filing says these may not be completed on acceptable terms.

Phase 2a Trial, Natera Tie-Up and Listing Status

General and administrative expense rose to USD 3.8 million in the quarter from USD 1.4 million, while research and development expense was USD 3.5 million against USD 3.2 million. The company recently started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, run with Quantum Leap Healthcare Collaborative, and on October 13, 2026 announced a collaboration with Natera to support enrollment. A licensing agreement signed March 2, 2026 with Unleash Immuno Oncolytics added a preclinical adenovirus program. After a May 2026 Nasdaq equity deficiency letter, the exchange confirmed compliance following conversion of the Series A preferred stock. A November 6, 2026 settlement of the Wheeler Action involved no cash payment. About 17.3 million shares were outstanding on November 12, 2026, after the preferred stock conversion added 15,872,258 common shares between July 20 and August 10, 2026.

Where Things Stand

Because an asset acquired for stock lost most of its carrying value while funding stayed thin. TransCode Therapeutics (NASDAQ:RNAZ) wrote down USD 102.0 million of Seviprotimut-L, a non-cash charge, and holds about USD 4.6 million of cash against Going Concern doubt. Management expects cash to last into around the first quarter of 2027, and the board is running a formal strategic process. Next markers are any Waiver from Yorkville, progress in the Phase 2a trial and the outcome of the strategic review.